Peter D. Emanuel
Professor
faculty
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Peter D. Emanuel is a researcher whose work focuses on the genomic landscape and cellular mechanisms underlying pediatric myeloid neoplasms. He investigates the genetic alterations and clonal architecture present in these conditions, particularly those involving chromosome 7 deletions. His research has explored the sensitivity of juvenile myelomonocytic leukemia (JMML) stem cells to natural killer (NK) cell-mediated lysis and identified targetable antigens on these cells. Emanuel also examines potential therapeutic strategies, including the investigation of MLN0128 as a targeted therapy for myeloid proliferation neoplasia, with a focus on its potential to prolong survival.
His laboratory is equipped with advanced sequencing technology, supported by a $750,000 grant from the NIH/National Institute of General Medical Sciences for a NovaSeq X Plus sequencer. This infrastructure facilitates his research into the molecular underpinnings of these hematologic malignancies. Emanuel has published over 100 scholarly works, with a citation count exceeding 3,500 and an h-index of 32. He is recognized as a high-impact, highly cited researcher and a principal investigator on federal grants.
Metrics
- h-index: 32
- Publications: 108
- Citations: 3,560
Selected Publications
-
Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens (2025)
Federal Grants 1 $750,000 total
Collaboration Network
Top Collaborators
- MLN0128, a Potential Target Therapy for Myeloid Proliferation Neoplasia (MPN) with a Benefit of Prolonging Survival
- Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens
- Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions
- Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens
- MLN0128, a Potential Target Therapy for Myeloid Proliferation Neoplasia (MPN) with a Benefit of Prolonging Survival
- MLN0128, a Potential Target Therapy for Myeloid Proliferation Neoplasia (MPN) with a Benefit of Prolonging Survival
- MLN0128, a Potential Target Therapy for Myeloid Proliferation Neoplasia (MPN) with a Benefit of Prolonging Survival
- Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions
- Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions
- Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions
- Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions
- Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions
- Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions
- Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions
- Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions
- Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions
- Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions
Similar Researchers
Based on overlapping research topics